ABTL-0812 is under clinical development by Ability Pharmaceuticals and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ABTL-0812’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABTL-0812 overview
ABTL-0812 is under development for the treatment of advanced solid tumors including pancreatic cancer, biliary tract cancer, lung carcinoma, endometrial cancer, non-small cell lung cancer, adult and pediatric neuroblastoma, glioblastoma. It is administered orally. The drug candidate targets AKT, PI3K, dihydrofolate reductase (DHFR) and mTORC1/C2 and is developed based on membrane lipid therapy. It was also under development for the treatment of breast cancer and glioma.
Ability Pharmaceuticals overview
Ability Pharmaceuticals (Ability Pharma) is a clinical stage drug discovery and development biopharmaceutical company. The company discovers and develops human therapeutics for the treatment of cancer and other indications. Ability Pharma offers lead pipeline drug candidate such as ABTL0812, a new drug class of small molecules, developed for the treatment of lung and endometrial cancer. It offers treatment for lung, pancreatic and gynecological cancers. The company works in partnership with academic institutions to develop new drug candidates up to clinical proof of concept and later out-license them to pharmaceutical companies for development and marketing. Ability Pharma is headquartered in Barcelona City, Barcelona, Spain.
For a complete picture of ABTL-0812’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
